Search

Your search keyword '"Kundra, Vikas"' showing total 489 results

Search Constraints

Start Over You searched for: Author "Kundra, Vikas" Remove constraint Author: "Kundra, Vikas"
489 results on '"Kundra, Vikas"'

Search Results

1. Erythrocyte nano-ghosts with dual optical and magnetic resonance characteristics.

2. Density-based Isometric Mapping

4. Indocyanine Green (ICG) Fluorescence Is Dependent on Monomer with Planar and Twisted Structures and Inhibited by H-Aggregation

8. Near Infrared Fluorescence Imaging of Intraperitoneal Ovarian Tumors in Mice Using Erythrocyte-Derived Optical Nanoparticles and Spatially-Modulated Illumination.

10. Contributors

12. Effects of excitation angle strategy on quantitative analysis of hyperpolarized pyruvate

22. Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells

24. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells.

25. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

27. Data from Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

28. Supplementary Figures 1-3, Tables 1-2 from Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

30. Table S2 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

31. Legend of Supplementary Figures from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

33. Figure S7 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

34. Supplementary Methods from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

35. Supplementary Data from Pharmacodynamic Markers of Perifosine Efficacy

36. Supplementary Results from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

37. Table S1 addendum from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

38. Supplementary Figures 1-5 from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

39. Supplementary Figure 1 from Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma

40. Supplementary Legends 1-2 from Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma

41. Supplementary Figure 2 from Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma

42. Data from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

43. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer

Catalog

Books, media, physical & digital resources